nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—Daunorubicin—hematologic cancer	0.0866	0.145	CbGbCtD
Eprosartan—CYP2C9—Bexarotene—hematologic cancer	0.0496	0.0828	CbGbCtD
Eprosartan—ABCC2—Irinotecan—hematologic cancer	0.0414	0.0692	CbGbCtD
Eprosartan—CYP2C9—Idarubicin—hematologic cancer	0.0411	0.0686	CbGbCtD
Eprosartan—ABCC2—Vinblastine—hematologic cancer	0.0368	0.0615	CbGbCtD
Eprosartan—ABCC2—Vincristine—hematologic cancer	0.0362	0.0604	CbGbCtD
Eprosartan—ABCC2—Cisplatin—hematologic cancer	0.0338	0.0564	CbGbCtD
Eprosartan—ABCC2—Etoposide—hematologic cancer	0.0332	0.0554	CbGbCtD
Eprosartan—CYP2C9—Bortezomib—hematologic cancer	0.0304	0.0508	CbGbCtD
Eprosartan—ABCC2—Dexamethasone—hematologic cancer	0.0273	0.0455	CbGbCtD
Eprosartan—CYP2C9—Thalidomide—hematologic cancer	0.0265	0.0442	CbGbCtD
Eprosartan—CYP2C9—Teniposide—hematologic cancer	0.0253	0.0422	CbGbCtD
Eprosartan—CYP2C9—Ifosfamide—hematologic cancer	0.0233	0.0389	CbGbCtD
Eprosartan—ABCC2—Doxorubicin—hematologic cancer	0.0226	0.0378	CbGbCtD
Eprosartan—CYP2C9—Imatinib—hematologic cancer	0.0223	0.0372	CbGbCtD
Eprosartan—ABCC2—Methotrexate—hematologic cancer	0.0219	0.0366	CbGbCtD
Eprosartan—CYP2C9—Nilotinib—hematologic cancer	0.0202	0.0338	CbGbCtD
Eprosartan—CYP2C9—Cisplatin—hematologic cancer	0.0113	0.0189	CbGbCtD
Eprosartan—CYP2C9—Dexamethasone—hematologic cancer	0.00916	0.0153	CbGbCtD
Eprosartan—Losartan—UGT1A1—hematologic cancer	0.00145	0.676	CrCbGaD
Eprosartan—Losartan—ALB—hematologic cancer	0.000356	0.166	CrCbGaD
Eprosartan—Losartan—ABCB1—hematologic cancer	0.000339	0.158	CrCbGaD
Eprosartan—AGTR1—Signaling Pathways—GNA13—hematologic cancer	5.22e-05	0.000759	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—IL3—hematologic cancer	5.19e-05	0.000756	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—TFRC—hematologic cancer	5.14e-05	0.000748	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TIAM1—hematologic cancer	5.13e-05	0.000747	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GBA—hematologic cancer	5.07e-05	0.000738	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—RASGRP1—hematologic cancer	5.02e-05	0.000731	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CCL2—hematologic cancer	5e-05	0.000727	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JAK3—hematologic cancer	4.98e-05	0.000724	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—PIK3CA—hematologic cancer	4.97e-05	0.000723	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCR4—hematologic cancer	4.89e-05	0.000712	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—hematologic cancer	4.84e-05	0.000704	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL13—hematologic cancer	4.77e-05	0.000694	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCR7—hematologic cancer	4.77e-05	0.000694	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL3—hematologic cancer	4.72e-05	0.000687	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NCOR2—hematologic cancer	4.71e-05	0.000685	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL3RA—hematologic cancer	4.65e-05	0.000677	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CRKL—hematologic cancer	4.65e-05	0.000677	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTP1—hematologic cancer	4.57e-05	0.000665	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—RASGRP1—hematologic cancer	4.56e-05	0.000664	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—GRB2—hematologic cancer	4.52e-05	0.000658	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTP1—hematologic cancer	4.51e-05	0.000656	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RGS2—hematologic cancer	4.48e-05	0.000653	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—hematologic cancer	4.44e-05	0.000647	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—TGFB1—hematologic cancer	4.44e-05	0.000647	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TRH—hematologic cancer	4.43e-05	0.000646	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TRIO—hematologic cancer	4.43e-05	0.000646	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CMA1—hematologic cancer	4.43e-05	0.000646	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AGO2—hematologic cancer	4.34e-05	0.000632	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SPHK1—hematologic cancer	4.34e-05	0.000632	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—CYCS—hematologic cancer	4.31e-05	0.000627	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LPAR1—hematologic cancer	4.29e-05	0.000625	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HDAC9—hematologic cancer	4.29e-05	0.000625	CbGpPWpGaD
Eprosartan—Vomiting—Gemcitabine—hematologic cancer	4.29e-05	0.00013	CcSEcCtD
Eprosartan—Insomnia—Dexamethasone—hematologic cancer	4.29e-05	0.00013	CcSEcCtD
Eprosartan—Insomnia—Betamethasone—hematologic cancer	4.29e-05	0.00013	CcSEcCtD
Eprosartan—Bradycardia—Doxorubicin—hematologic cancer	4.28e-05	0.00013	CcSEcCtD
Eprosartan—Paraesthesia—Betamethasone—hematologic cancer	4.26e-05	0.000129	CcSEcCtD
Eprosartan—Paraesthesia—Dexamethasone—hematologic cancer	4.26e-05	0.000129	CcSEcCtD
Eprosartan—Discomfort—Prednisone—hematologic cancer	4.25e-05	0.000129	CcSEcCtD
Eprosartan—Rash—Gemcitabine—hematologic cancer	4.25e-05	0.000129	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—H3F3B—hematologic cancer	4.25e-05	0.000619	CbGpPWpGaD
Eprosartan—Dermatitis—Gemcitabine—hematologic cancer	4.25e-05	0.000129	CcSEcCtD
Eprosartan—Hypersensitivity—Etoposide—hematologic cancer	4.24e-05	0.000128	CcSEcCtD
Eprosartan—Tinnitus—Epirubicin—hematologic cancer	4.24e-05	0.000128	CcSEcCtD
Eprosartan—Headache—Gemcitabine—hematologic cancer	4.23e-05	0.000128	CcSEcCtD
Eprosartan—Nausea—Vincristine—hematologic cancer	4.22e-05	0.000128	CcSEcCtD
Eprosartan—Rhinitis—Doxorubicin—hematologic cancer	4.22e-05	0.000128	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—GSTM1—hematologic cancer	4.2e-05	0.000611	CbGpPWpGaD
Eprosartan—Hypersensitivity—Prednisolone—hematologic cancer	4.19e-05	0.000127	CcSEcCtD
Eprosartan—Pharyngitis—Doxorubicin—hematologic cancer	4.17e-05	0.000126	CcSEcCtD
Eprosartan—Dyspepsia—Dexamethasone—hematologic cancer	4.17e-05	0.000126	CcSEcCtD
Eprosartan—Dyspepsia—Betamethasone—hematologic cancer	4.17e-05	0.000126	CcSEcCtD
Eprosartan—Urticaria—Triamcinolone—hematologic cancer	4.15e-05	0.000126	CcSEcCtD
Eprosartan—Oedema peripheral—Doxorubicin—hematologic cancer	4.14e-05	0.000125	CcSEcCtD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTM1—hematologic cancer	4.14e-05	0.000603	CbGpPWpGaD
Eprosartan—Asthenia—Etoposide—hematologic cancer	4.13e-05	0.000125	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—FHL2—hematologic cancer	4.13e-05	0.000601	CbGpPWpGaD
Eprosartan—Body temperature increased—Triamcinolone—hematologic cancer	4.13e-05	0.000125	CcSEcCtD
Eprosartan—Decreased appetite—Dexamethasone—hematologic cancer	4.12e-05	0.000125	CcSEcCtD
Eprosartan—Decreased appetite—Betamethasone—hematologic cancer	4.12e-05	0.000125	CcSEcCtD
Eprosartan—Nausea—Irinotecan—hematologic cancer	4.11e-05	0.000125	CcSEcCtD
Eprosartan—Nausea—Mitoxantrone—hematologic cancer	4.11e-05	0.000125	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—hematologic cancer	4.11e-05	0.000598	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—GRB2—hematologic cancer	4.1e-05	0.000597	CbGpPWpGaD
Eprosartan—Back pain—Methotrexate—hematologic cancer	4.09e-05	0.000124	CcSEcCtD
Eprosartan—Fatigue—Dexamethasone—hematologic cancer	4.09e-05	0.000124	CcSEcCtD
Eprosartan—Fatigue—Betamethasone—hematologic cancer	4.09e-05	0.000124	CcSEcCtD
Eprosartan—Chills—Epirubicin—hematologic cancer	4.08e-05	0.000123	CcSEcCtD
Eprosartan—Pruritus—Etoposide—hematologic cancer	4.07e-05	0.000123	CcSEcCtD
Eprosartan—Shock—Prednisone—hematologic cancer	4.06e-05	0.000123	CcSEcCtD
Eprosartan—Pain—Dexamethasone—hematologic cancer	4.05e-05	0.000123	CcSEcCtD
Eprosartan—Pain—Betamethasone—hematologic cancer	4.05e-05	0.000123	CcSEcCtD
Eprosartan—Visual impairment—Doxorubicin—hematologic cancer	4.05e-05	0.000123	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—CSF2—hematologic cancer	4.04e-05	0.000588	CbGpPWpGaD
Eprosartan—Tachycardia—Prednisone—hematologic cancer	4.03e-05	0.000122	CcSEcCtD
Eprosartan—Nausea—Gemcitabine—hematologic cancer	4.01e-05	0.000121	CcSEcCtD
Eprosartan—Vomiting—Cisplatin—hematologic cancer	4e-05	0.000121	CcSEcCtD
Eprosartan—Hyperhidrosis—Prednisone—hematologic cancer	3.99e-05	0.000121	CcSEcCtD
Eprosartan—Rash—Cisplatin—hematologic cancer	3.96e-05	0.00012	CcSEcCtD
Eprosartan—Dermatitis—Cisplatin—hematologic cancer	3.96e-05	0.00012	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PDE4B—hematologic cancer	3.95e-05	0.000575	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CNR2—hematologic cancer	3.95e-05	0.000575	CbGpPWpGaD
Eprosartan—Diarrhoea—Etoposide—hematologic cancer	3.94e-05	0.000119	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hematologic cancer	3.93e-05	0.000573	CbGpPWpGaD
Eprosartan—Anorexia—Prednisone—hematologic cancer	3.93e-05	0.000119	CcSEcCtD
Eprosartan—Ill-defined disorder—Methotrexate—hematologic cancer	3.92e-05	0.000119	CcSEcCtD
Eprosartan—Tinnitus—Doxorubicin—hematologic cancer	3.92e-05	0.000119	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—FGF19—hematologic cancer	3.92e-05	0.000571	CbGpPWpGaD
Eprosartan—Feeling abnormal—Betamethasone—hematologic cancer	3.91e-05	0.000118	CcSEcCtD
Eprosartan—Feeling abnormal—Dexamethasone—hematologic cancer	3.91e-05	0.000118	CcSEcCtD
Eprosartan—Flatulence—Epirubicin—hematologic cancer	3.9e-05	0.000118	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—PRKCG—hematologic cancer	3.9e-05	0.000567	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—JAK1—hematologic cancer	3.9e-05	0.000567	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RAC2—hematologic cancer	3.89e-05	0.000566	CbGpPWpGaD
Eprosartan—Tension—Epirubicin—hematologic cancer	3.88e-05	0.000118	CcSEcCtD
Eprosartan—Gastrointestinal pain—Betamethasone—hematologic cancer	3.88e-05	0.000117	CcSEcCtD
Eprosartan—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.88e-05	0.000117	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—DKK1—hematologic cancer	3.86e-05	0.000562	CbGpPWpGaD
Eprosartan—Hypersensitivity—Triamcinolone—hematologic cancer	3.85e-05	0.000117	CcSEcCtD
Eprosartan—Nervousness—Epirubicin—hematologic cancer	3.84e-05	0.000116	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—STAT5B—hematologic cancer	3.83e-05	0.000557	CbGpPWpGaD
Eprosartan—Back pain—Epirubicin—hematologic cancer	3.83e-05	0.000116	CcSEcCtD
Eprosartan—Malaise—Methotrexate—hematologic cancer	3.81e-05	0.000115	CcSEcCtD
Eprosartan—Dizziness—Etoposide—hematologic cancer	3.81e-05	0.000115	CcSEcCtD
Eprosartan—Muscle spasms—Epirubicin—hematologic cancer	3.8e-05	0.000115	CcSEcCtD
Eprosartan—Vertigo—Methotrexate—hematologic cancer	3.8e-05	0.000115	CcSEcCtD
Eprosartan—Chills—Doxorubicin—hematologic cancer	3.77e-05	0.000114	CcSEcCtD
Eprosartan—Urticaria—Betamethasone—hematologic cancer	3.77e-05	0.000114	CcSEcCtD
Eprosartan—Urticaria—Dexamethasone—hematologic cancer	3.77e-05	0.000114	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.76e-05	0.000114	CcSEcCtD
Eprosartan—Dizziness—Prednisolone—hematologic cancer	3.76e-05	0.000114	CcSEcCtD
Eprosartan—Asthenia—Triamcinolone—hematologic cancer	3.75e-05	0.000113	CcSEcCtD
Eprosartan—Abdominal pain—Dexamethasone—hematologic cancer	3.75e-05	0.000113	CcSEcCtD
Eprosartan—Body temperature increased—Betamethasone—hematologic cancer	3.75e-05	0.000113	CcSEcCtD
Eprosartan—Body temperature increased—Dexamethasone—hematologic cancer	3.75e-05	0.000113	CcSEcCtD
Eprosartan—Abdominal pain—Betamethasone—hematologic cancer	3.75e-05	0.000113	CcSEcCtD
Eprosartan—Nausea—Cisplatin—hematologic cancer	3.73e-05	0.000113	CcSEcCtD
Eprosartan—Insomnia—Prednisone—hematologic cancer	3.73e-05	0.000113	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—ADCY7—hematologic cancer	3.72e-05	0.000541	CbGpPWpGaD
Eprosartan—Paraesthesia—Prednisone—hematologic cancer	3.71e-05	0.000112	CcSEcCtD
Eprosartan—Pruritus—Triamcinolone—hematologic cancer	3.7e-05	0.000112	CcSEcCtD
Eprosartan—Cough—Methotrexate—hematologic cancer	3.69e-05	0.000112	CcSEcCtD
Eprosartan—Ill-defined disorder—Epirubicin—hematologic cancer	3.67e-05	0.000111	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—CSF2—hematologic cancer	3.67e-05	0.000534	CbGpPWpGaD
Eprosartan—Vomiting—Etoposide—hematologic cancer	3.66e-05	0.000111	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—IL2RA—hematologic cancer	3.64e-05	0.00053	CbGpPWpGaD
Eprosartan—Dyspepsia—Prednisone—hematologic cancer	3.63e-05	0.00011	CcSEcCtD
Eprosartan—Rash—Etoposide—hematologic cancer	3.63e-05	0.00011	CcSEcCtD
Eprosartan—Dermatitis—Etoposide—hematologic cancer	3.63e-05	0.00011	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—XIAP—hematologic cancer	3.61e-05	0.000526	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ARNTL—hematologic cancer	3.61e-05	0.000526	CbGpPWpGaD
Eprosartan—Headache—Etoposide—hematologic cancer	3.61e-05	0.000109	CcSEcCtD
Eprosartan—Flatulence—Doxorubicin—hematologic cancer	3.61e-05	0.000109	CcSEcCtD
Eprosartan—Arthralgia—Methotrexate—hematologic cancer	3.6e-05	0.000109	CcSEcCtD
Eprosartan—Chest pain—Methotrexate—hematologic cancer	3.6e-05	0.000109	CcSEcCtD
Eprosartan—Myalgia—Methotrexate—hematologic cancer	3.6e-05	0.000109	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCB1—hematologic cancer	3.6e-05	0.000523	CbGpPWpGaD
Eprosartan—Tension—Doxorubicin—hematologic cancer	3.59e-05	0.000109	CcSEcCtD
Eprosartan—Decreased appetite—Prednisone—hematologic cancer	3.59e-05	0.000109	CcSEcCtD
Eprosartan—Rash—Prednisolone—hematologic cancer	3.58e-05	0.000108	CcSEcCtD
Eprosartan—Dermatitis—Prednisolone—hematologic cancer	3.58e-05	0.000108	CcSEcCtD
Eprosartan—Malaise—Epirubicin—hematologic cancer	3.57e-05	0.000108	CcSEcCtD
Eprosartan—Fatigue—Prednisone—hematologic cancer	3.56e-05	0.000108	CcSEcCtD
Eprosartan—Headache—Prednisolone—hematologic cancer	3.56e-05	0.000108	CcSEcCtD
Eprosartan—Discomfort—Methotrexate—hematologic cancer	3.56e-05	0.000108	CcSEcCtD
Eprosartan—Nervousness—Doxorubicin—hematologic cancer	3.56e-05	0.000108	CcSEcCtD
Eprosartan—Vertigo—Epirubicin—hematologic cancer	3.55e-05	0.000108	CcSEcCtD
Eprosartan—Syncope—Epirubicin—hematologic cancer	3.55e-05	0.000107	CcSEcCtD
Eprosartan—Back pain—Doxorubicin—hematologic cancer	3.54e-05	0.000107	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—JAK1—hematologic cancer	3.54e-05	0.000515	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PRKCG—hematologic cancer	3.54e-05	0.000515	CbGpPWpGaD
Eprosartan—Constipation—Prednisone—hematologic cancer	3.53e-05	0.000107	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—SMARCA4—hematologic cancer	3.52e-05	0.000513	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SH2B3—hematologic cancer	3.52e-05	0.000513	CbGpPWpGaD
Eprosartan—Muscle spasms—Doxorubicin—hematologic cancer	3.52e-05	0.000107	CcSEcCtD
Eprosartan—CYP2C9—Metabolism—FTCD—hematologic cancer	3.5e-05	0.00051	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GMPS—hematologic cancer	3.5e-05	0.00051	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PHYH—hematologic cancer	3.5e-05	0.00051	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GZMB—hematologic cancer	3.5e-05	0.00051	CbGpPWpGaD
Eprosartan—Palpitations—Epirubicin—hematologic cancer	3.5e-05	0.000106	CcSEcCtD
Eprosartan—Loss of consciousness—Epirubicin—hematologic cancer	3.48e-05	0.000105	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR2—hematologic cancer	3.47e-05	0.000505	CbGpPWpGaD
Eprosartan—Dizziness—Triamcinolone—hematologic cancer	3.45e-05	0.000105	CcSEcCtD
Eprosartan—Cough—Epirubicin—hematologic cancer	3.45e-05	0.000105	CcSEcCtD
Eprosartan—Nausea—Etoposide—hematologic cancer	3.42e-05	0.000104	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—CTNNA1—hematologic cancer	3.42e-05	0.000498	CbGpPWpGaD
Eprosartan—Feeling abnormal—Prednisone—hematologic cancer	3.4e-05	0.000103	CcSEcCtD
Eprosartan—Asthenia—Dexamethasone—hematologic cancer	3.4e-05	0.000103	CcSEcCtD
Eprosartan—Asthenia—Betamethasone—hematologic cancer	3.4e-05	0.000103	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—HSPB1—hematologic cancer	3.4e-05	0.000495	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCL3—hematologic cancer	3.4e-05	0.000495	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EIF4EBP1—hematologic cancer	3.4e-05	0.000495	CbGpPWpGaD
Eprosartan—Ill-defined disorder—Doxorubicin—hematologic cancer	3.4e-05	0.000103	CcSEcCtD
Eprosartan—Thrombocytopenia—Methotrexate—hematologic cancer	3.38e-05	0.000102	CcSEcCtD
Eprosartan—Gastrointestinal pain—Prednisone—hematologic cancer	3.38e-05	0.000102	CcSEcCtD
Eprosartan—Nausea—Prednisolone—hematologic cancer	3.37e-05	0.000102	CcSEcCtD
Eprosartan—Chest pain—Epirubicin—hematologic cancer	3.37e-05	0.000102	CcSEcCtD
Eprosartan—Myalgia—Epirubicin—hematologic cancer	3.37e-05	0.000102	CcSEcCtD
Eprosartan—Arthralgia—Epirubicin—hematologic cancer	3.37e-05	0.000102	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—SDC1—hematologic cancer	3.36e-05	0.000489	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTHLH—hematologic cancer	3.36e-05	0.000489	CbGpPWpGaD
Eprosartan—Anxiety—Epirubicin—hematologic cancer	3.36e-05	0.000102	CcSEcCtD
Eprosartan—Pruritus—Betamethasone—hematologic cancer	3.35e-05	0.000102	CcSEcCtD
Eprosartan—Pruritus—Dexamethasone—hematologic cancer	3.35e-05	0.000102	CcSEcCtD
Eprosartan—Hyperhidrosis—Methotrexate—hematologic cancer	3.34e-05	0.000101	CcSEcCtD
Eprosartan—Discomfort—Epirubicin—hematologic cancer	3.33e-05	0.000101	CcSEcCtD
Eprosartan—Vomiting—Triamcinolone—hematologic cancer	3.32e-05	0.000101	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—IL2RA—hematologic cancer	3.3e-05	0.000481	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	3.3e-05	0.000481	CbGpPWpGaD
Eprosartan—Malaise—Doxorubicin—hematologic cancer	3.3e-05	9.99e-05	CcSEcCtD
Eprosartan—Rash—Triamcinolone—hematologic cancer	3.29e-05	9.97e-05	CcSEcCtD
Eprosartan—Dry mouth—Epirubicin—hematologic cancer	3.29e-05	9.97e-05	CcSEcCtD
Eprosartan—Dermatitis—Triamcinolone—hematologic cancer	3.29e-05	9.96e-05	CcSEcCtD
Eprosartan—Vertigo—Doxorubicin—hematologic cancer	3.29e-05	9.96e-05	CcSEcCtD
Eprosartan—Anorexia—Methotrexate—hematologic cancer	3.29e-05	9.96e-05	CcSEcCtD
Eprosartan—Syncope—Doxorubicin—hematologic cancer	3.28e-05	9.94e-05	CcSEcCtD
Eprosartan—Urticaria—Prednisone—hematologic cancer	3.28e-05	9.93e-05	CcSEcCtD
Eprosartan—Headache—Triamcinolone—hematologic cancer	3.27e-05	9.91e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PTGER4—hematologic cancer	3.27e-05	0.000476	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	3.26e-05	0.000475	CbGpPWpGaD
Eprosartan—Body temperature increased—Prednisone—hematologic cancer	3.26e-05	9.88e-05	CcSEcCtD
Eprosartan—Abdominal pain—Prednisone—hematologic cancer	3.26e-05	9.88e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—LCK—hematologic cancer	3.25e-05	0.000474	CbGpPWpGaD
Eprosartan—Diarrhoea—Dexamethasone—hematologic cancer	3.24e-05	9.82e-05	CcSEcCtD
Eprosartan—Diarrhoea—Betamethasone—hematologic cancer	3.24e-05	9.82e-05	CcSEcCtD
Eprosartan—Palpitations—Doxorubicin—hematologic cancer	3.23e-05	9.79e-05	CcSEcCtD
Eprosartan—Hypotension—Methotrexate—hematologic cancer	3.22e-05	9.76e-05	CcSEcCtD
Eprosartan—Loss of consciousness—Doxorubicin—hematologic cancer	3.22e-05	9.74e-05	CcSEcCtD
Eprosartan—CYP2C9—Metabolism—SMPD3—hematologic cancer	3.2e-05	0.000466	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	3.19e-05	0.000465	CbGpPWpGaD
Eprosartan—Cough—Doxorubicin—hematologic cancer	3.19e-05	9.67e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—H3F3A—hematologic cancer	3.19e-05	0.000464	CbGpPWpGaD
Eprosartan—Shock—Epirubicin—hematologic cancer	3.18e-05	9.62e-05	CcSEcCtD
Eprosartan—Thrombocytopenia—Epirubicin—hematologic cancer	3.16e-05	9.57e-05	CcSEcCtD
Eprosartan—Tachycardia—Epirubicin—hematologic cancer	3.15e-05	9.54e-05	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Methotrexate—hematologic cancer	3.14e-05	9.52e-05	CcSEcCtD
Eprosartan—Dizziness—Betamethasone—hematologic cancer	3.13e-05	9.49e-05	CcSEcCtD
Eprosartan—Dizziness—Dexamethasone—hematologic cancer	3.13e-05	9.49e-05	CcSEcCtD
Eprosartan—Hyperhidrosis—Epirubicin—hematologic cancer	3.12e-05	9.45e-05	CcSEcCtD
Eprosartan—Insomnia—Methotrexate—hematologic cancer	3.12e-05	9.45e-05	CcSEcCtD
Eprosartan—Myalgia—Doxorubicin—hematologic cancer	3.12e-05	9.43e-05	CcSEcCtD
Eprosartan—Chest pain—Doxorubicin—hematologic cancer	3.12e-05	9.43e-05	CcSEcCtD
Eprosartan—Arthralgia—Doxorubicin—hematologic cancer	3.12e-05	9.43e-05	CcSEcCtD
Eprosartan—Anxiety—Doxorubicin—hematologic cancer	3.11e-05	9.4e-05	CcSEcCtD
Eprosartan—Nausea—Triamcinolone—hematologic cancer	3.1e-05	9.39e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PRKCZ—hematologic cancer	3.1e-05	0.000451	CbGpPWpGaD
Eprosartan—Paraesthesia—Methotrexate—hematologic cancer	3.1e-05	9.38e-05	CcSEcCtD
Eprosartan—Discomfort—Doxorubicin—hematologic cancer	3.08e-05	9.32e-05	CcSEcCtD
Eprosartan—Anorexia—Epirubicin—hematologic cancer	3.08e-05	9.32e-05	CcSEcCtD
Eprosartan—Dyspnoea—Methotrexate—hematologic cancer	3.08e-05	9.31e-05	CcSEcCtD
Eprosartan—Somnolence—Methotrexate—hematologic cancer	3.07e-05	9.29e-05	CcSEcCtD
Eprosartan—Dry mouth—Doxorubicin—hematologic cancer	3.05e-05	9.23e-05	CcSEcCtD
Eprosartan—Hypersensitivity—Prednisone—hematologic cancer	3.04e-05	9.21e-05	CcSEcCtD
Eprosartan—Dyspepsia—Methotrexate—hematologic cancer	3.04e-05	9.19e-05	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CG—hematologic cancer	3.03e-05	0.000441	CbGpPWpGaD
Eprosartan—Hypotension—Epirubicin—hematologic cancer	3.02e-05	9.13e-05	CcSEcCtD
Eprosartan—Vomiting—Dexamethasone—hematologic cancer	3.01e-05	9.12e-05	CcSEcCtD
Eprosartan—Vomiting—Betamethasone—hematologic cancer	3.01e-05	9.12e-05	CcSEcCtD
Eprosartan—Decreased appetite—Methotrexate—hematologic cancer	3e-05	9.08e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PARP1—hematologic cancer	3e-05	0.000436	CbGpPWpGaD
Eprosartan—Rash—Betamethasone—hematologic cancer	2.99e-05	9.05e-05	CcSEcCtD
Eprosartan—Rash—Dexamethasone—hematologic cancer	2.99e-05	9.05e-05	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	2.99e-05	0.000435	CbGpPWpGaD
Eprosartan—Dermatitis—Betamethasone—hematologic cancer	2.99e-05	9.04e-05	CcSEcCtD
Eprosartan—Dermatitis—Dexamethasone—hematologic cancer	2.99e-05	9.04e-05	CcSEcCtD
Eprosartan—Fatigue—Methotrexate—hematologic cancer	2.97e-05	9.01e-05	CcSEcCtD
Eprosartan—Headache—Dexamethasone—hematologic cancer	2.97e-05	8.99e-05	CcSEcCtD
Eprosartan—Headache—Betamethasone—hematologic cancer	2.97e-05	8.99e-05	CcSEcCtD
Eprosartan—Asthenia—Prednisone—hematologic cancer	2.96e-05	8.97e-05	CcSEcCtD
Eprosartan—Pain—Methotrexate—hematologic cancer	2.95e-05	8.93e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—FBXW7—hematologic cancer	2.95e-05	0.000429	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.94e-05	8.91e-05	CcSEcCtD
Eprosartan—Shock—Doxorubicin—hematologic cancer	2.94e-05	8.9e-05	CcSEcCtD
Eprosartan—Thrombocytopenia—Doxorubicin—hematologic cancer	2.92e-05	8.86e-05	CcSEcCtD
Eprosartan—Pruritus—Prednisone—hematologic cancer	2.92e-05	8.84e-05	CcSEcCtD
Eprosartan—Insomnia—Epirubicin—hematologic cancer	2.92e-05	8.84e-05	CcSEcCtD
Eprosartan—Tachycardia—Doxorubicin—hematologic cancer	2.92e-05	8.83e-05	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	2.91e-05	0.000424	CbGpPWpGaD
Eprosartan—Paraesthesia—Epirubicin—hematologic cancer	2.9e-05	8.78e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—HDAC2—hematologic cancer	2.89e-05	0.000421	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCR4—hematologic cancer	2.89e-05	0.000421	CbGpPWpGaD
Eprosartan—Hyperhidrosis—Doxorubicin—hematologic cancer	2.89e-05	8.74e-05	CcSEcCtD
Eprosartan—Dyspnoea—Epirubicin—hematologic cancer	2.88e-05	8.71e-05	CcSEcCtD
Eprosartan—Somnolence—Epirubicin—hematologic cancer	2.87e-05	8.69e-05	CcSEcCtD
Eprosartan—Anorexia—Doxorubicin—hematologic cancer	2.85e-05	8.62e-05	CcSEcCtD
Eprosartan—Feeling abnormal—Methotrexate—hematologic cancer	2.84e-05	8.61e-05	CcSEcCtD
Eprosartan—Dyspepsia—Epirubicin—hematologic cancer	2.84e-05	8.6e-05	CcSEcCtD
Eprosartan—Diarrhoea—Prednisone—hematologic cancer	2.82e-05	8.55e-05	CcSEcCtD
Eprosartan—Gastrointestinal pain—Methotrexate—hematologic cancer	2.82e-05	8.54e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—CBL—hematologic cancer	2.82e-05	0.00041	CbGpPWpGaD
Eprosartan—Nausea—Dexamethasone—hematologic cancer	2.82e-05	8.52e-05	CcSEcCtD
Eprosartan—Nausea—Betamethasone—hematologic cancer	2.82e-05	8.52e-05	CcSEcCtD
Eprosartan—Decreased appetite—Epirubicin—hematologic cancer	2.81e-05	8.5e-05	CcSEcCtD
Eprosartan—CYP2C9—Metabolism—DCK—hematologic cancer	2.8e-05	0.000407	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ASNS—hematologic cancer	2.8e-05	0.000407	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—B3GAT1—hematologic cancer	2.8e-05	0.000407	CbGpPWpGaD
Eprosartan—Hypotension—Doxorubicin—hematologic cancer	2.79e-05	8.45e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—IL3—hematologic cancer	2.79e-05	0.000406	CbGpPWpGaD
Eprosartan—Fatigue—Epirubicin—hematologic cancer	2.78e-05	8.43e-05	CcSEcCtD
Eprosartan—Pain—Epirubicin—hematologic cancer	2.76e-05	8.36e-05	CcSEcCtD
Eprosartan—Constipation—Epirubicin—hematologic cancer	2.76e-05	8.36e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CG—hematologic cancer	2.75e-05	0.000401	CbGpPWpGaD
Eprosartan—Urticaria—Methotrexate—hematologic cancer	2.74e-05	8.3e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PTPN1—hematologic cancer	2.74e-05	0.000399	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	2.74e-05	0.000398	CbGpPWpGaD
Eprosartan—Dizziness—Prednisone—hematologic cancer	2.73e-05	8.26e-05	CcSEcCtD
Eprosartan—Body temperature increased—Methotrexate—hematologic cancer	2.73e-05	8.26e-05	CcSEcCtD
Eprosartan—Abdominal pain—Methotrexate—hematologic cancer	2.73e-05	8.26e-05	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.72e-05	8.24e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—PTPN11—hematologic cancer	2.7e-05	0.000394	CbGpPWpGaD
Eprosartan—Insomnia—Doxorubicin—hematologic cancer	2.7e-05	8.18e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—RASGRP1—hematologic cancer	2.7e-05	0.000392	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SYK—hematologic cancer	2.69e-05	0.000391	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HSP90AA1—hematologic cancer	2.69e-05	0.000391	CbGpPWpGaD
Eprosartan—Paraesthesia—Doxorubicin—hematologic cancer	2.68e-05	8.12e-05	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CD—hematologic cancer	2.66e-05	0.000388	CbGpPWpGaD
Eprosartan—Dyspnoea—Doxorubicin—hematologic cancer	2.66e-05	8.06e-05	CcSEcCtD
Eprosartan—Feeling abnormal—Epirubicin—hematologic cancer	2.66e-05	8.05e-05	CcSEcCtD
Eprosartan—Somnolence—Doxorubicin—hematologic cancer	2.66e-05	8.04e-05	CcSEcCtD
Eprosartan—CYP2C9—Metabolism—HDC—hematologic cancer	2.65e-05	0.000386	CbGpPWpGaD
Eprosartan—Gastrointestinal pain—Epirubicin—hematologic cancer	2.64e-05	7.99e-05	CcSEcCtD
Eprosartan—Dyspepsia—Doxorubicin—hematologic cancer	2.63e-05	7.96e-05	CcSEcCtD
Eprosartan—Vomiting—Prednisone—hematologic cancer	2.62e-05	7.95e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—CREB1—hematologic cancer	2.62e-05	0.000381	CbGpPWpGaD
Eprosartan—Rash—Prednisone—hematologic cancer	2.6e-05	7.88e-05	CcSEcCtD
Eprosartan—Dermatitis—Prednisone—hematologic cancer	2.6e-05	7.87e-05	CcSEcCtD
Eprosartan—Decreased appetite—Doxorubicin—hematologic cancer	2.6e-05	7.86e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—STAT1—hematologic cancer	2.59e-05	0.000377	CbGpPWpGaD
Eprosartan—Headache—Prednisone—hematologic cancer	2.59e-05	7.83e-05	CcSEcCtD
Eprosartan—Fatigue—Doxorubicin—hematologic cancer	2.58e-05	7.8e-05	CcSEcCtD
Eprosartan—Urticaria—Epirubicin—hematologic cancer	2.56e-05	7.77e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—CCL2—hematologic cancer	2.56e-05	0.000373	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6R—hematologic cancer	2.56e-05	0.000372	CbGpPWpGaD
Eprosartan—Pain—Doxorubicin—hematologic cancer	2.55e-05	7.73e-05	CcSEcCtD
Eprosartan—Constipation—Doxorubicin—hematologic cancer	2.55e-05	7.73e-05	CcSEcCtD
Eprosartan—Abdominal pain—Epirubicin—hematologic cancer	2.55e-05	7.73e-05	CcSEcCtD
Eprosartan—Body temperature increased—Epirubicin—hematologic cancer	2.55e-05	7.73e-05	CcSEcCtD
Eprosartan—Hypersensitivity—Methotrexate—hematologic cancer	2.54e-05	7.7e-05	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3R1—hematologic cancer	2.52e-05	0.000366	CbGpPWpGaD
Eprosartan—Asthenia—Methotrexate—hematologic cancer	2.48e-05	7.49e-05	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	2.47e-05	0.00036	CbGpPWpGaD
Eprosartan—Feeling abnormal—Doxorubicin—hematologic cancer	2.46e-05	7.45e-05	CcSEcCtD
Eprosartan—Nausea—Prednisone—hematologic cancer	2.45e-05	7.42e-05	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—JAK2—hematologic cancer	2.45e-05	0.000356	CbGpPWpGaD
Eprosartan—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.44e-05	7.4e-05	CcSEcCtD
Eprosartan—Pruritus—Methotrexate—hematologic cancer	2.44e-05	7.39e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—MAP2K1—hematologic cancer	2.44e-05	0.000355	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CDA—hematologic cancer	2.43e-05	0.000353	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GRB2—hematologic cancer	2.42e-05	0.000353	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CD—hematologic cancer	2.42e-05	0.000352	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PDGFA—hematologic cancer	2.42e-05	0.000352	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.4e-05	0.00035	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KITLG—hematologic cancer	2.38e-05	0.000347	CbGpPWpGaD
Eprosartan—Hypersensitivity—Epirubicin—hematologic cancer	2.38e-05	7.2e-05	CcSEcCtD
Eprosartan—Urticaria—Doxorubicin—hematologic cancer	2.37e-05	7.18e-05	CcSEcCtD
Eprosartan—Body temperature increased—Doxorubicin—hematologic cancer	2.36e-05	7.15e-05	CcSEcCtD
Eprosartan—Abdominal pain—Doxorubicin—hematologic cancer	2.36e-05	7.15e-05	CcSEcCtD
Eprosartan—Diarrhoea—Methotrexate—hematologic cancer	2.36e-05	7.15e-05	CcSEcCtD
Eprosartan—CYP2C9—Metabolism—PC—hematologic cancer	2.34e-05	0.00034	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STAT5A—hematologic cancer	2.33e-05	0.000339	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CB—hematologic cancer	2.32e-05	0.000338	CbGpPWpGaD
Eprosartan—Asthenia—Epirubicin—hematologic cancer	2.32e-05	7.01e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—CDKN2B—hematologic cancer	2.31e-05	0.000336	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3R1—hematologic cancer	2.29e-05	0.000333	CbGpPWpGaD
Eprosartan—Pruritus—Epirubicin—hematologic cancer	2.28e-05	6.92e-05	CcSEcCtD
Eprosartan—Dizziness—Methotrexate—hematologic cancer	2.28e-05	6.91e-05	CcSEcCtD
Eprosartan—CYP2C9—Metabolism—GBA—hematologic cancer	2.26e-05	0.000328	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC35B2—hematologic cancer	2.26e-05	0.000328	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ALB—hematologic cancer	2.25e-05	0.000327	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CD86—hematologic cancer	2.23e-05	0.000325	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—JAK2—hematologic cancer	2.22e-05	0.000323	CbGpPWpGaD
Eprosartan—Diarrhoea—Epirubicin—hematologic cancer	2.21e-05	6.69e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—HES1—hematologic cancer	2.2e-05	0.000321	CbGpPWpGaD
Eprosartan—Hypersensitivity—Doxorubicin—hematologic cancer	2.2e-05	6.66e-05	CcSEcCtD
Eprosartan—Vomiting—Methotrexate—hematologic cancer	2.19e-05	6.64e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—NCOR1—hematologic cancer	2.19e-05	0.000319	CbGpPWpGaD
Eprosartan—Rash—Methotrexate—hematologic cancer	2.18e-05	6.59e-05	CcSEcCtD
Eprosartan—Dermatitis—Methotrexate—hematologic cancer	2.17e-05	6.58e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—FGF1—hematologic cancer	2.17e-05	0.000315	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CSF2—hematologic cancer	2.17e-05	0.000315	CbGpPWpGaD
Eprosartan—Headache—Methotrexate—hematologic cancer	2.16e-05	6.54e-05	CcSEcCtD
Eprosartan—Asthenia—Doxorubicin—hematologic cancer	2.14e-05	6.49e-05	CcSEcCtD
Eprosartan—Dizziness—Epirubicin—hematologic cancer	2.13e-05	6.46e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—FOXO1—hematologic cancer	2.13e-05	0.000311	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—IL2—hematologic cancer	2.13e-05	0.000311	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PDGFRB—hematologic cancer	2.13e-05	0.00031	CbGpPWpGaD
Eprosartan—Pruritus—Doxorubicin—hematologic cancer	2.11e-05	6.4e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CB—hematologic cancer	2.11e-05	0.000307	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PDGFRA—hematologic cancer	2.1e-05	0.000305	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JAK1—hematologic cancer	2.09e-05	0.000304	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PRKCG—hematologic cancer	2.09e-05	0.000304	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTAP—hematologic cancer	2.06e-05	0.0003	CbGpPWpGaD
Eprosartan—Vomiting—Epirubicin—hematologic cancer	2.05e-05	6.21e-05	CcSEcCtD
Eprosartan—Nausea—Methotrexate—hematologic cancer	2.05e-05	6.2e-05	CcSEcCtD
Eprosartan—Diarrhoea—Doxorubicin—hematologic cancer	2.04e-05	6.19e-05	CcSEcCtD
Eprosartan—Rash—Epirubicin—hematologic cancer	2.04e-05	6.16e-05	CcSEcCtD
Eprosartan—Dermatitis—Epirubicin—hematologic cancer	2.03e-05	6.16e-05	CcSEcCtD
Eprosartan—Headache—Epirubicin—hematologic cancer	2.02e-05	6.12e-05	CcSEcCtD
Eprosartan—Dizziness—Doxorubicin—hematologic cancer	1.98e-05	5.98e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—IL2RA—hematologic cancer	1.95e-05	0.000284	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL2—hematologic cancer	1.94e-05	0.000282	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TERT—hematologic cancer	1.93e-05	0.000281	CbGpPWpGaD
Eprosartan—Nausea—Epirubicin—hematologic cancer	1.92e-05	5.81e-05	CcSEcCtD
Eprosartan—Vomiting—Doxorubicin—hematologic cancer	1.9e-05	5.75e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PDGFB—hematologic cancer	1.88e-05	0.000274	CbGpPWpGaD
Eprosartan—Rash—Doxorubicin—hematologic cancer	1.88e-05	5.7e-05	CcSEcCtD
Eprosartan—Dermatitis—Doxorubicin—hematologic cancer	1.88e-05	5.7e-05	CcSEcCtD
Eprosartan—Headache—Doxorubicin—hematologic cancer	1.87e-05	5.67e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—TSC2—hematologic cancer	1.84e-05	0.000268	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—FHL2—hematologic cancer	1.84e-05	0.000268	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AGRN—hematologic cancer	1.8e-05	0.000263	CbGpPWpGaD
Eprosartan—Nausea—Doxorubicin—hematologic cancer	1.77e-05	5.37e-05	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—FGFR3—hematologic cancer	1.77e-05	0.000258	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAPK14—hematologic cancer	1.75e-05	0.000255	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ESR1—hematologic cancer	1.72e-05	0.00025	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—IDH2—hematologic cancer	1.71e-05	0.000249	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HMMR—hematologic cancer	1.71e-05	0.000249	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FN1—hematologic cancer	1.7e-05	0.000247	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BAD—hematologic cancer	1.68e-05	0.000244	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NFKBIA—hematologic cancer	1.68e-05	0.000244	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH1—hematologic cancer	1.66e-05	0.000242	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CD80—hematologic cancer	1.63e-05	0.000237	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KIT—hematologic cancer	1.63e-05	0.000237	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CG—hematologic cancer	1.63e-05	0.000237	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—NRAS—hematologic cancer	1.63e-05	0.000237	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.61e-05	0.000235	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ARNTL—hematologic cancer	1.61e-05	0.000234	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTPN11—hematologic cancer	1.6e-05	0.000233	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CA9—hematologic cancer	1.56e-05	0.000228	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ACP5—hematologic cancer	1.56e-05	0.000228	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—MAPK3—hematologic cancer	1.56e-05	0.000227	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CREB1—hematologic cancer	1.55e-05	0.000225	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOR2—hematologic cancer	1.54e-05	0.000225	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BRAF—hematologic cancer	1.53e-05	0.000223	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCL2—hematologic cancer	1.51e-05	0.00022	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6R—hematologic cancer	1.51e-05	0.00022	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CREBBP—hematologic cancer	1.51e-05	0.000219	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—IDH1—hematologic cancer	1.47e-05	0.000214	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TXN—hematologic cancer	1.45e-05	0.000212	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCC3—hematologic cancer	1.45e-05	0.000212	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTO1—hematologic cancer	1.45e-05	0.000212	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAP2K1—hematologic cancer	1.44e-05	0.000209	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CD—hematologic cancer	1.43e-05	0.000208	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SPHK1—hematologic cancer	1.42e-05	0.000207	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.42e-05	0.000206	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—KRAS—hematologic cancer	1.4e-05	0.000204	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGF2—hematologic cancer	1.37e-05	0.000199	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—UGT1A1—hematologic cancer	1.37e-05	0.000199	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3R1—hematologic cancer	1.35e-05	0.000197	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CRABP1—hematologic cancer	1.33e-05	0.000194	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC22A1—hematologic cancer	1.33e-05	0.000194	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JAK2—hematologic cancer	1.31e-05	0.000191	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALOX5—hematologic cancer	1.3e-05	0.000189	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CA—hematologic cancer	1.29e-05	0.000187	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MDM2—hematologic cancer	1.28e-05	0.000186	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NUP98—hematologic cancer	1.26e-05	0.000183	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CB—hematologic cancer	1.25e-05	0.000181	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MTOR—hematologic cancer	1.25e-05	0.000181	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ADCY7—hematologic cancer	1.22e-05	0.000177	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOA3—hematologic cancer	1.22e-05	0.000177	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NUP214—hematologic cancer	1.21e-05	0.000176	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.2e-05	0.000174	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—HRAS—hematologic cancer	1.19e-05	0.000173	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCG2—hematologic cancer	1.19e-05	0.000173	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTR—hematologic cancer	1.19e-05	0.000173	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN1B—hematologic cancer	1.17e-05	0.00017	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ENO2—hematologic cancer	1.16e-05	0.000169	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKT1—hematologic cancer	1.16e-05	0.000168	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CASP3—hematologic cancer	1.15e-05	0.000167	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL2—hematologic cancer	1.14e-05	0.000167	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6—hematologic cancer	1.14e-05	0.000166	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTT1—hematologic cancer	1.13e-05	0.000164	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCND1—hematologic cancer	1.12e-05	0.000162	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JUN—hematologic cancer	1.11e-05	0.000162	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.11e-05	0.000162	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SDC1—hematologic cancer	1.1e-05	0.00016	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN1A—hematologic cancer	1.08e-05	0.000157	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTEN—hematologic cancer	1.08e-05	0.000157	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAPK8—hematologic cancer	1.05e-05	0.000153	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.05e-05	0.000153	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKT1—hematologic cancer	1.05e-05	0.000153	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.04e-05	0.000151	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EP300—hematologic cancer	1.03e-05	0.000149	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SRC—hematologic cancer	9.99e-06	0.000145	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	9.94e-06	0.000145	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VEGFA—hematologic cancer	9.73e-06	0.000142	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STAT3—hematologic cancer	9.63e-06	0.00014	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NRAS—hematologic cancer	9.61e-06	0.00014	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CD44—hematologic cancer	9.37e-06	0.000136	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NQO1—hematologic cancer	9.37e-06	0.000136	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAPK3—hematologic cancer	9.2e-06	0.000134	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	9.17e-06	0.000134	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MYC—hematologic cancer	8.95e-06	0.00013	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFB1—hematologic cancer	8.93e-06	0.00013	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYCS—hematologic cancer	8.87e-06	0.000129	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	8.81e-06	0.000128	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KRAS—hematologic cancer	8.27e-06	0.00012	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	7.93e-06	0.000115	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTP1—hematologic cancer	7.81e-06	0.000114	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CA—hematologic cancer	7.6e-06	0.000111	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	7.56e-06	0.00011	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCB1—hematologic cancer	7.4e-06	0.000108	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—hematologic cancer	7.35e-06	0.000107	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTM1—hematologic cancer	7.18e-06	0.000105	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOR1—hematologic cancer	7.18e-06	0.000105	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HRAS—hematologic cancer	7.03e-06	0.000102	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6—hematologic cancer	6.73e-06	9.79e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTHFR—hematologic cancer	6.35e-06	9.24e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKT1—hematologic cancer	6.21e-06	9.03e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.59e-06	8.14e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CG—hematologic cancer	5.33e-06	7.76e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CREBBP—hematologic cancer	4.94e-06	7.2e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CD—hematologic cancer	4.69e-06	6.82e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALB—hematologic cancer	4.63e-06	6.74e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3R1—hematologic cancer	4.43e-06	6.44e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CB—hematologic cancer	4.09e-06	5.95e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTEN—hematologic cancer	3.53e-06	5.14e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—EP300—hematologic cancer	3.37e-06	4.9e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CA—hematologic cancer	2.49e-06	3.63e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AKT1—hematologic cancer	2.03e-06	2.96e-05	CbGpPWpGaD
